Previous 10 | Next 10 |
Gainers: Ayro (NASDAQ: AYRO ) +102% . More news on: Ayro, Inc., Electrameccanica Vehicles Corp., LM Funding America, Inc., Stocks on the move, , Read more ...
ObsEva SA ( OBSV -41.8% ) slumps on more than a 7x surge in volume on the heels of results from two Phase 3 clinical trials evaluating lead candidate linzagolix in women with heavy menstrual bleeding due to uterine fibroids. More news on: ObsEva SA, AbbVie Inc., Myovant Sciences Ltd., ...
ObsEva SA (NASDAQ: OBSV ) announces positive results from a Phase 3 clinical trial, PRIMROSE 1 , evaluating Yselty (linzagolix) in women with heavy menstrual bleeding due to uterine fibroids. More news on: ObsEva SA, Healthcare stocks news, Stocks on the move, Read more ...
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2 results demonstrate sustained efficacy and continued safety of linzagolix at week 52 Results confirm linzagolix as a p...
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that they will present at ESHRE Vir...
ObsEva's (NASDAQ: OBSV ) partner Yuyuan BioScience Technology has submitted a pre-IND meeting request for nolasiban to the Center for Drug Evaluation at the Chinese National Medical Products Administration. More news on: ObsEva SA, Healthcare stocks news, Read more ...
Geneva, Switzerland and Boston, MA – July 1, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN - a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reprod...
Geneva, Switzerland and Boston, MA – June 29, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release Phase ...
Geneva, Switzerland and Boston, MA – June 9, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive he...
GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) , a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported publication in the journal Fertility and Sterility of...
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...